B. Riley Issues Positive Forecast for Cytokinetics (NASDAQ:CYTK) Stock Price
B. Riley raised their price target on Cytokinetics from $74.00 to $80.00 and gave the stock a “buy” rating in a research report on Monday.
Source link
Similar Posts
AMD vs. NVIDIA: Which Tech Giant Will Dominate the Future of AI? 🤖
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, will adversely affect certain features and functions. The technical storage or access is strictly…
November 15th COVID Update: COVID in Wastewater Continues to Decline
by Calculated Risk on 11/15/2024 07:46:00 PM Note: Mortgage rates are from MortgageNewsDaily.com and are for top tier scenarios. For deaths, I’m currently using 4 weeks ago for “now”, since the most recent three weeks will be revised significantly. Note: “Effective May 1, 2024, hospitals are no longer required to report COVID-19 hospital admissions, hospital…
2 Top TSX Dividend Stocks With Yields Above 5%
Retirees and other income investors are searching for good Canadian dividend stocks to buy for their self-directed Tax-Free Savings Account (TFSA) portfolios. The big jump in the TSX over the past year wiped out some of the best deals in the market, but investors can still find good high-yield dividend stocks trading at reasonable prices….
Where I’d Invest $5,900 in the TSX Today
Are you looking to invest a “medium-sized” sum of money — let’s say $5,900? If so, you need to know where you will put that money to work. While it’s tempting to talk to a bank advisor and invest in whatever they recommend, this sometimes results in you being invested in high fee funds. So,…
The 2 Best TSX Stocks to Buy Before They Recover
The TSX continues to display powerful resilience amid heightened volatility. As of mid-April 2026, the index has climbed 7.7% year-to-date, with eight of 11 primary sectors now in positive territory. Buying opportunities are plenty, too, as many underperforming but high-quality stocks have clear paths to rise. TELUS (TSX:T) and Propel Holdings (TSX:PRL) belong in the…
